INM
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number is N/A due to negative earnings; valuation is based purely on assets/sales which are declining.
- Low P/B (0.21)
- Low P/S (0.53)
- Classic value trap characteristics
- Negative earnings make P/E irrelevant
Growth metrics are trending downward across both YoY and Q/Q timeframes.
- Recent slight Q/Q EPS improvement
- Revenue growth is negative (-26.2%)
- Operating margins are deeply negative
Historical price performance indicates a total loss of investor confidence.
- 5Y Change: -100%
- 1Y Change: -71.7%
High liquidity is likely a result of cash reserves being burned rather than operational cash flow.
- Low Debt/Equity
- High Current Ratio
- Piotroski F-Score 1/9
- ROE of -97.20%
Dividend yield is N/A.
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INM and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INM
InMed Pharmaceuticals Inc.
Primary
|
-100.0% | -97.1% | -71.7% | -66.3% | -10.5% | +5.6% |
|
HCWB
HCW Biologics Inc.
Peer
|
-99.9% | -99.4% | -96.3% | -91.0% | -30.6% | +36.0% |
|
IMCC
IM Cannabis Corp.
Peer
|
-99.9% | -91.4% | -72.7% | -81.3% | -57.0% | +6.5% |
|
HCTI
Healthcare Triangle, Inc.
Peer
|
-100.0% | -100.0% | -99.9% | -98.6% | -21.6% | -2.8% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INM
InMed Pharmaceuticals Inc.
|
BEARISH | $2.37M | - | -97.2% | -170.1% | $0.72 | |
|
HCWB
HCW Biologics Inc.
|
BEARISH | $2.45M | - | -% | -% | $0.36 | Compare |
|
IMCC
IM Cannabis Corp.
|
BEARISH | $2.25M | - | -% | -20.7% | $0.36 | Compare |
|
HCTI
Healthcare Triangle, Inc.
|
BEARISH | $2.77M | - | -183.0% | -48.8% | $2.4 | Compare |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
Past News Coverage
Recent headlines mentioning INM from our newsroom.